ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

ClinicalTrials.gov ID: NCT04889430

Public ClinicalTrials.gov record NCT04889430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy

Study identification

NCT ID
NCT04889430
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
34 participants

Conditions and interventions

Interventions

  • Iptacopan Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 16, 2022
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update posted
May 5, 2026

2022 – 2026

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
14
Facility City State ZIP Site status
USC Norris Cancer Center Los Angeles California 90033
Univ of California at Los Angeles Los Angeles California 90095
Univ Cali Irvine ALS Neuromuscular Orange California 92868
Univ of California at Sacramento Sacramento California 95817
Harbor-UCLA Medical Center . Torrance California 90502
Georgetown University Lombardi Cancer Center Washington D.C. District of Columbia 20007-2197
University Of Miami Miami Florida 33136
University of Minnesota Minneapolis Minnesota 55455
Montefiore Medical Center . The Bronx New York 10461
Montefiore Medical Center The Bronx New York 10461
Duke University Medical Center Durham North Carolina 27710
University of Cincinnati Cincinnati Ohio 45267-0585
Cleveland Clinic Foundation Cleveland Ohio 44195
Comprehensive Transplant Ctr at OSU Columbus Ohio 43210
UT Southwestern Medical Center Dallas Texas 75390
Virginia Commonwealth University Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04889430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04889430 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →